ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach

Ting-Shuan Wu; Tzu-Hung Hsiao; Chung-Hsing Chen; Hsin-Ni Li; Miao-Neng Hung; Pei-Pei Jhan; Jia-Rung Tsai; Chieh-Lin Jerry Teng

doi:10.1186/s12014-025-09527-7

ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink^® proteomics approach

Clin Proteomics. 2025 Jan 21;22(1):3. doi: 10.1186/s12014-025-09527-7.

Authors

Ting-Shuan Wu^#^{1

2}, Tzu-Hung Hsiao^#^{3

4

5

6}, Chung-Hsing Chen⁷, Hsin-Ni Li^{8

9}, Miao-Neng Hung¹, Pei-Pei Jhan³, Jia-Rung Tsai¹⁰, Chieh-Lin Jerry Teng^{11

12

13

14

15

16}

Affiliations

¹ Department of Biomedical Sciences, Chung Shan Medical University, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan.
² Department of Medical Research, Chung Shan Medical University Hospital, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan.
³ Department of Medical Research, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
⁴ Research Center for Biomedical Science and Engineering, National Tsing Hua University, Sect 2, Kuang-Fu Rd, Hsinchu, 101, 300044, Taiwan.
⁵ Department of Public Health, Fu Jen Catholic University, No. 510, Zhongzheng Rd, New Taipei City, 242062, Taiwan.
⁶ Institute of Genomics and Bioinformatics, National Chung Hsing University, No. 145 Xingda Rd., South Dist, Taichung, 402202, Taiwan.
⁷ Department of Mathematics, University of Taipei, No. 1 Ai-Guo West Rd, Taipei, 100234, Taiwan.
⁸ Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
⁹ Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, No. 145 Xingda Rd., South Dist, Taichung, 402202, Taiwan.
¹⁰ Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
¹¹ Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan. [email protected].
¹² Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, No. 145 Xingda Rd., South Dist, Taichung, 402202, Taiwan. [email protected].
¹³ Department of Life Science, Tunghai University, No. 1727, Sect. 4, Taiwan boulevard, Taichung, 407224, Taiwan. [email protected].
¹⁴ School of Medicine, Chung Shan Medical University, No. 110, Sect. 1, Jiangou North Rd, Taichung, 40201, Taiwan. [email protected].
¹⁵ Ph.D. Program in Translational Medicine, National Chung Hsing University, No. 145 Xingda Rd., South Dist, Taichung, 402202, Taiwan. [email protected].
¹⁶ Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, No. 145 Xingda Rd., South Dist, Taichung, 402202, Taiwan. [email protected].

^# Contributed equally.

PMID: 39833682
DOI: 10.1186/s12014-025-09527-7

Abstract

Background: The standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink^® platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following "7 + 3" induction treatment.

Methods: This prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy. We employed the Olink^® Explore-384 Inflammation platform for proteomic analysis to investigate differences in bone marrow plasma protein levels between the CR and non-CR groups.

Results: Proteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.

Conclusions: The results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the "7 + 3" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.

Keywords: ARTN; Acute myeloid leukemia; CCL23; Chemosensitivity; Olink®; Proteomics.

Abstract

Grants and funding